Questions about this study?
The HopeStage team will email you.
TerminatedNCT00645515
A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia
Medication studyAges 18–70Spain
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
- Listed locations
- Bilbao and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateJune 2003
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 240
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Spain
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00645515
- Official title
Show the full official title
Ziprasidone Versus Risperidone In The Treatment Of Chronic Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study
Recruitment & locations
TerminatedBilbao · Getxo · Madrid
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Does this study involve medication?
Yes. The study involves medication, including Ziprasidone and Risperidone.
Who can participate?
Listed age limits: 18 years to 70 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me